Genotyping of a Family with a Novel Deleterious DPYD Mutation Supports the Pretherapeutic Screening of DPD Deficiency with Dihydrouracil/Uracil Ratio

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 2, 2016, Pages 235-241

  Thomas, F ^a,b   Hennebelle, I ^a,b   Delmas, C ^a,b   Lochon, I ^a,b   Dhelens, C ^c   Tixidre, C Garnier ^d   Bonadona, A ^c   Penel, N ^e   Goncalves, A ^f   Delord, J P ^a,b   Toulas, C ^a   Chatelut, E ^a,b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c HÔPITAL MICHALLON   (France)

^d Institut Daniel Hollard   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DIHYDROURACIL; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; URACIL; ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA;

ADULT; ARTICLE; BLOOD LEVEL; CAUCASIAN; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DPYD GENE; FAMILY; FEMALE; GENE; GENE DUPLICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; CASE REPORT; FATALITY; GENETIC VARIATION; GENETICS; METABOLISM; MUTATION;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; BIOTRANSFORMATION; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DIHYDROURACIL DEHYDROGENASE (NADP); DNA; FAMILY; FATAL OUTCOME; FEMALE; FLUOROURACIL; GENE DUPLICATION; GENETIC VARIATION; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; RETROSPECTIVE STUDIES; URACIL;

EID: 84970925333     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.210     Document Type: Article

References (50)

1. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J. Clin. Oncol. 16, 3537-3541 (1998).
2. Lu, Z., Zhang, R., Carpenter, J. T. & Diasio, R. B. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 4, 325-329 (1998).
3. Etienne, M. C. et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J. Clin. Oncol. 12, 2248-2253 (1994).
4. Kuilenburg, A. B. P. van. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 40, 939-950 (2004).
5. Deenen, M. J. et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 17, 3455-3468 (2011).
6. Caudle, K. E. et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 94, 640-645 (2013).
7. Amstutz, U., Froehlich, T. K. & Largiadèr, C. R. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12, 1321-1336 (2011).
8. Rosmarin, D. et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J. Clin. Oncol. 32, 1031-1039 (2014).
9. Lee, A. M. et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J. Natl. Cancer Inst. 106, dju298 (2014).
10. Kristensen, M. H., Pedersen, P. & Mejer, J. The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. J. Int. Med. Res. 38, 1313-1323 (2010).
11. Gamelin, E. et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol. 17, 1105-1110 (1999).
12. Boisdron-Celle, M. et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 249, 271-282 (2007).
13. Dhelens, C. et al. Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency. Letter to the Editor. Int. J. Colorectal Dis., published online (doi:10. 1007/s00384-015-2191-0).
14. Kuilenburg, A. B. P. van. et al. Dihydropyrimidine dehydrogenase deficiency caused by a novel genomic deletion c. 505-513del of DPYD. Nucleosides Nucleotides Nucleic Acids 29, 509-514 (2010).
15. Kuilenburg, A. B. van. et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS1411G>A mutation causing DPD deficiency. Clin. Cancer Res. 7, 1149-1153 (2001).
16. Kuilenburg, A. B. P. van. et al. Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13. 3p21. 3). Hum. Genet. 125, 581-590 (2009).
17. Kuilenburg, A. B. P. van. et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem. J. 364, 157-163 (2002).
18. Vreken, P., Kuilenburg, A. B. Van, Meinsma, R. & Gennip, A. H. van. Identification of novel point mutations in the dihydropyrimidine dehydrogenase gene. J. Inherit. Metab. Dis. 20, 335-338 (1997).
19. Vreken, P. et al. Dihydropyrimidine dehydrogenase deficiency: a novel mutation and expression of missense mutations in E. coli. J. Inherit. Metab. Dis. 21, 276-279 (1998).
20. Kuilenburg, A. B. P. van, Baars, J. W., Meinsma, R. & Gennip, A. H. van. Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene. Ann. Oncol. 14, 341-342 (2003).
21. Johnson, M. R., Wang, K. & Diasio, R. B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 8, 768-774 (2002).
22. CPIC Dosing Guideline for fluorouracil and DPYD. .
23. Offer, S. M., Wegner, N. J., Fossum, C., Wang, K. & Diasio, R. B. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 73, 1958-1968 (2013).
24. Amstutz, U., Farese, S., Aebi, S. & Largiadèr, C. R. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 10, 931-944 (2009).
25. DPYD-SNP-NCBI. . Accessed July 2015.
26. Exome Variant Server. . Accessed July 2015.
27. 1000 Genomes Project Browser. . Accessed July 2015.
28. Offer, S. M. et al. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 74, 2545-2554 (2014).
29. Dobritzsch, D., Schneider, G., Schnackerz, K. D. & Lindqvist, Y. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J. 20, 650-660 (2001).
30. Schwab, M. et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26, 2131-2138 (2008).
31. Ezzeldin, H. H., Lee, A. M., Mattison, L. K. & Diasio, R. B. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res. 11, 8699-8705 (2005).
32. Offer, S. M. et al. microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol. Cancer Ther. 13, 742-751 (2014).
33. Ciccolini, J., Gross, E., Dahan, L., Lacarelle, B. & Mercier, C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin. Colorectal Cancer 9, 224-228 (2010).
34. Staveren, M. C. van, Jan Guchelaar, H., Kuilenburg, A. B. P. van, Gelderblom, H. & Maring, J. G. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J. 13, 389-395 (2013).
35. Offer, S. M. et al. A DPYD variant (Y186C) in individuals of African ancestry associated with reduced DPD enzyme activity. Clin. Pharmacol. Ther. 94, 158-166 (2013).
36. Saif, M. W. et al. A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clin. Proc. 89, 131-136 (2014).
37. Kuilenburg, A. B. P. van. et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum. Genet. 128, 529-538 (2010).
38. Froehlich, T. K., Amstutz, U., Aebi, S., Joerger, M. & Largiadèr, C. R. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int. J. Cancer 136, 730-739 (2015).
39. Rosmarin, D. et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut 64, 111-120 (2015).
40. Morel, A., Boisdron-Celle, M., Fey, L., Lainé-Cessac, P. & Gamelin, E. Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma. Clin. Biochem. 40, 11-17 (2007).
41. Ezzeldin, H., Johnson, M. R., Okamoto, Y. & Diasio, R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin. Cancer Res. 9, 3021-3028 (2003).
42. Gross, E. et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS ONE 3 (2008).
43. Etienne-Grimaldi, M. C. et al. Exhaustive single nucleotide polymorphism (SNP) analysis of DPYD exome in breast cancer patients (pts) receiving capecitabine [abstract 2571]. ASCO Meeting (2015).
44. Coudoré, F. et al. Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5, 6-dihydrouracil in human plasma. J. Chromatogr. Sci. 50, 877-884 (2012).
45. Sistonen, J. et al. Predicting 5-fluorouracil toxicity: DPD genotype and 5, 6-dihydrouracil:uracil ratio. Pharmacogenomics 15, 1653-1666 (2014).
46. Kuilenburg, A. B. van. et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracilassociated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6, 4705-4712 (2000).
47. Gamelin, E. et al. Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. J. Chromatogr. B. Biomed. Sci. App. 695, 409-416 (1997).
48. Remaud, G., Boisdron-Celle, M., Hameline, C., Morel, A. & Gamelin, E. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 823, 98-107 (2005).
49. Frédéric, M. Y. et al. UMD-predictor, a new prediction tool for nucleotide substitution pathogenicity - application to four genes: FBN1, FBN2, TGFBR1, and TGFBR2. Hum. Mutat. 30, 952-959 (2009).
50. UMD-Predictor. . Accessed July 2015.